Palisade Bio Stock (NASDAQ:PALI)

Revenue Ownership Financials Chart

Previous Close

$2.09

52W Range

$0.53 - $2.86

50D Avg

$2.03

200D Avg

$1.94

Market Cap

$381.88M

Avg Vol (3M)

$2.81M

Beta

1.55

Div Yield

PALI Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 30, 2007

Website

PALI Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Mar 23
License	$300.00

Fiscal year ends in Dec 25 | Currency in USD

PALI Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	$250.00K
Operating Income	$-18.06M	$-14.86M	$-13.07M
Net Income	$-16.78M	$-14.44M	$-12.30M
EBITDA	$-18.06M	$-14.42M	$-12.28M
Basic EPS	$-0.30	$-10.19	$-27.01
Diluted EPS	$-0.30	$-10.19	$-27.01

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
DARE	Dare Bioscience, Inc.
ASBP	Aspire Biopharma Holdings, Inc.
CRIS	Curis, Inc.
CTXR	Citius Pharmaceuticals, Inc.
BCTX	BriaCell Therapeutics Corp.
PCSA	Processa Pharmaceuticals, Inc.
ATHA	Athira Pharma, Inc.
LPTX	Leap Therapeutics, Inc.